Background: Pustular psoriasis is an uncommon psoriasis variant, clinically characterized as small sterile pustules on an erythematous base. Evidence for therapy is lacking, and many currently employed systemic therapeutics carry risks of significant side effects, without specifically targeting disease etiology which includes the aggregation of neutrophils. Observations: We report therapy with the anti-neutrophil agent dapsone in 5 patients with pustular psoriasis and provide a brief review of the literature. Four patients responded to oral dapsone and 1 to topical dapsone therapy. All 5 patients had previously failed multiple topical and systemic treatments. In 2 cases, oral dapsone allowed for the discontinuation of other systemic agents. One patient stopped oral dapsone due to a side effect of sleep disturbance. Conclusion: Dapsone has a much safer side effect profile and may target the pathophysiology of pustular psoriasis more directly than many other systemic agents. As such, dapsone should be considered for the treatment of patients with pustular psoriasis.

Keywords:
Dapsone, Glucose-6-phosphate dehydrogenase, Pustular psoriasis, Palmoplantar pustular psoriasis
1.
Mrowietz U, van de Kerkhof PC: Management of palmoplantar pustulosis: do we need to change? Br J Dermatol 2011;164:942-946.
2.
Ko JM, Gottlieb AB, Kerbleski JF: Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatol Treat 2009;20:100-108.
3.
Naik HB, Cowen EW: Autoinflammatory pustular neutrophilic diseases. Dermatol Clin 2013;31:405-425.
4.
Umezawa Y, et al: Therapeutic guidelines for the treatment of generalized pustular psoriasis (GPP) based on a proposed classification of disease severity. Arch Dermatol Res 2003;295(suppl 1):S43-S54.
5.
Wozel G, Blasum C: Dapsone in dermatology and beyond. Arch Dermatol Res 2014;306:103-124.
6.
Modschiedler K, et al: Dapsone and colchicine inhibit adhesion of neutrophilic granulocytes to epidermal sections. Arch Dermatol Res 2000;292:32-36.
7.
Macmillan AL, Champion RH: Generalized pustular psoriasis treated with dapsone. Br J Dermatol 1973;88:183-185.
8.
Juanqin G, Zhiqiang C, Zijia H: Evaluation of the effectiveness of childhood generalized pustular psoriasis treatment in 30 cases. Pediatr Dermatol 1998;15:144-146.
9.
Barlow RJ, Schulz EJ: Chronic subcorneal pustulosis with vasculitis: a variant of generalized pustular psoriasis in black South Africans. Br J Dermatol 1991;124:470-474.
10.
Singh N, Thappa DM: Circinate pustular psoriasis localized to glans penis mimicking ‘circinate balanitis' and responsive to dapsone. Indian J Dermatol Venereol Leprol 2008;74:388-389.
11.
Sommer S, et al: Sweet's syndrome presenting as palmoplantar pustulosis. J Am Acad Dermatol 2000;42(2 Pt 2):332-334.
12.
Zhu KJ, et al: Complete atrioventricular block associated with dapsone therapy: a rare complication of dapsone-induced hypersensitivity syndrome. J Clin Pharm Ther 2009;34:489-492.
13.
Robinson A, et al: Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2012;67:279-288.
14.
Bertelsen T, et al: Efficacy of ustekinumab in palmoplantar pustulosis and palmoplantar pustular psoriasis. Int J Dermatol 2014;53:e464-e466.
15.
Lutz V, Lipsker D: Acitretin- and tumor necrosis factor inhibitor-resistant acrodermatitis continua of Hallopeau responsive to the interleukin 1 receptor antagonist anakinra. Arch Dermatol 2012;148:297-299.
16.
Ghabril M, et al: Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol 2013;11:558-564.e3.
17.
Sevrain M, et al: Treatment for palmoplantar pustular psoriasis: systematic literature review, evidence-based recommendations and expert opinion. J Eur Acad Dermatol Venereol 2014;28(suppl 5):13-16.
18.
Lorenz M, Wozel G, Schmitt J: Hypersensitivity reactions to dapsone: a systematic review. Acta Derm Venereol 2012;92:194-199.
19.
Hornsten P, Keisu M, Wiholm BE: The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988. Arch Dermatol 1990;126:919-922.
20.
Orion E, Matz H, Wolf R: The life-threatening complications of dermatologic therapies. Clin Dermatol 2005;23:182-192.
21.
Bozeman PM, Learn DB, Thomas EL: Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapsone. Biochem Pharmacol 1992;44:553-563.
22.
van Zyl JM, et al: Mechanisms by which clofazimine and dapsone inhibit the myeloperoxidase system. A possible correlation with their anti-inflammatory properties. Biochem Pharmacol 1991;42:599-608.
23.
Wozel G, et al: Dapsone hydroxylamine inhibits the LTB4-induced chemotaxis of polymorphonuclear leukocytes into human skin: results of a pilot study. Inflamm Res 1997;46:420-422.
24.
Pfeiffer C, Wozel G: Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 2003;48:308-309.
25.
Strom BL, et al: Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 2003;349:1628-1635.
26.
Kelly JW, et al: Vitamin E and dapsone-induced hemolysis. Arch Dermatol 1984;120:1582-1584.
27.
Prussick R, et al: The protective effect of vitamin E on the hemolysis associated with dapsone treatment in patients with dermatitis herpetiformis. Arch Dermatol 1992;128:210-213.
28.
Coleman MD: Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol 1993;129:507-513.
29.
Dotsch J, et al: Reduction of NO-induced methemoglobinemia requires extremely high doses of ascorbic acid in vitro. Intensive Care Med 1998;24:612-615.
30.
Park SY, Lee KW, Kang TS: High-dose vitamin C management in dapsone-induced methemoglobinemia. Am J Emerg Med 2014;32:684.e1-3.
31.
Coleman MD, et al: The use of cimetidine to reduce dapsone-dependent methaemoglobinaemia in dermatitis herpetiformis patients. Br J Clin Pharmacol 1992;34:244-249.
32.
Coleman MD, Tingle MD, Park BK: Inhibition of dapsone-induced methaemoglobinaemia by cimetidine in the rat during chronic dapsone administration. J Pharm Pharmacol 1991;43:186-190.
33.
Rhodes LE, et al: Cimetidine improves the therapeutic/toxic ratio of dapsone in patients on chronic dapsone therapy. Br J Dermatol 1995;132:257-262.
34.
Dapsone: Administration/Monitoring. Micromedex 2.0. Truven Health Analytics, I.G.V., CO. http://www.micromedexsolutions.com (accessed Sept 30, 2014).
35.
Stotland M, Shalita AR, Kissling RF: Dapsone 5% gel: a review of its efficacy and safety in the treatment of acne vulgaris. Am J Clin Dermatol 2009;10:221-227.
36.
Smith N, et al: Acute treatment of generalized pustular psoriasis of von Zumbusch with single-dose infliximab. J Am Acad Dermatol 2013;68:e187-e189.
37.
Liao PB, et al: Annular pustular psoriasis - most common form of pustular psoriasis in children: report of three cases and review of the literature. Pediatr Dermatol 2002;19:19-25.
38.
Michaëlsson G, et al: Palmoplantar pustulosis and gluten sensitivity: a study of serum antibodies against gliadin and tissue transglutaminase, the duodenal mucosa and effects of gluten-free diet. Br J Dermatol 2007;156:659-666.
39.
Saunier J, et al: Acrodermatitis continua of Hallopeau treated successfully with ustekinumab and acitretin after failure of tumour necrosis factor blockade and anakinra. Dermatology 2015;230:97-100.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.